Growth Metrics

Edwards Lifesciences (EW) Cash from Investing Activities (2016 - 2026)

Edwards Lifesciences has reported Cash from Investing Activities over the past 17 years, most recently at -$198.3 million for Q4 2025.

  • For Q4 2025, Cash from Investing Activities rose 65.61% year-over-year to -$198.3 million; the TTM value through Dec 2025 reached -$712.9 million, down 130.82%, while the annual FY2025 figure was -$712.9 million, 130.82% down from the prior year.
  • Cash from Investing Activities for Q4 2025 was -$198.3 million at Edwards Lifesciences, up from -$427.8 million in the prior quarter.
  • Over five years, Cash from Investing Activities peaked at $2.7 billion in Q3 2024 and troughed at -$965.9 million in Q4 2021.
  • A 5-year average of $15.2 million and a median of $7.3 million in 2023 define the central range for Cash from Investing Activities.
  • On a YoY basis, Cash from Investing Activities climbed as much as 12520.0% in 2024 and fell as far as 4190.07% in 2024.
  • Year by year, Cash from Investing Activities stood at -$965.9 million in 2021, then surged by 109.8% to $94.7 million in 2022, then tumbled by 85.11% to $14.1 million in 2023, then crashed by 4190.07% to -$576.7 million in 2024, then skyrocketed by 65.61% to -$198.3 million in 2025.
  • Business Quant data shows Cash from Investing Activities for EW at -$198.3 million in Q4 2025, -$427.8 million in Q3 2025, and -$172.1 million in Q2 2025.